Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity.

Balaji M Rao1, Andrew T Girvin, Thomas Ciardelli

  • 1Department of Chemical Engineering and Biological Engineering Division, Massachusetts Institute of Technology, MIT 66-552, Cambridge, MA 02139, USA.

Protein Engineering
|February 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

In Memoriam: Robert M. Kelly (1953-2026).

Applied and environmental microbiology·2026
Same author

In Memoriam: Robert M. Kelly (1953-2026).

Applied and environmental microbiology·2026
Same author

Breast milk antibody Fc signatures track with HIV transmission during breastfeeding in ART-naïve mothers.

iScience·2026
Same author

A scalable, low-cost, sample hashing workflow for multiomic single-cell analysis using the Seq-Well S<sup>3</sup> platform.

Nature protocols·2026
Same author

Protein networks are influenced by maternal BMI and differentiate preterm birth types.

Communications medicine·2026

Researchers engineered interleukin-2 (IL-2) mutants with higher affinity for IL-2Ralpha, aiming to improve cancer therapies. These enhanced IL-2 variants show potential for more effective T-cell stimulation in treating metastatic cancers.

Area of Science:

  • Immunology
  • Biotechnology
  • Oncology

Background:

  • Interleukin-2 (IL-2) is used to treat metastatic renal carcinoma and melanoma.
  • Current IL-2 therapies face limitations due to a narrow therapeutic window, causing insufficient T-cell stimulation at low doses and excessive NK cell activation at high doses.

Purpose of the Study:

  • To engineer IL-2 mutants with increased affinity for the IL-2 receptor alpha subunit (IL-2Ralpha).
  • To develop IL-2 variants with enhanced biological potency for improved cancer immunotherapy.

Main Methods:

  • Screening libraries of mutated IL-2 displayed on yeast.
  • Isolation of IL-2 mutants with significantly improved binding affinity to IL-2Ralpha.

Main Results:

Related Experiment Videos

  • Identified IL-2 mutants with a 15-30 fold increase in affinity for IL-2Ralpha.
  • Mutants showed no significant change in bioactivity at low picomolar concentrations (0.5-5 pM).
  • One mutant demonstrated slightly improved potency, possibly due to altered endocytic trafficking.

    • Conclusions:

    • Increased IL-2 affinity for IL-2Ralpha is a viable strategy for developing more potent IL-2 variants.
    • Engineered IL-2 mutants hold promise for overcoming limitations in current IL-2-based cancer immunotherapies.
    • Further research into the mechanisms of enhanced IL-2 mutants could refine therapeutic applications.